These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

225 related articles for article (PubMed ID: 8260370)

  • 21. The thresholds for statistical and clinical significance - a five-step procedure for evaluation of intervention effects in randomised clinical trials.
    Jakobsen JC; Gluud C; Winkel P; Lange T; Wetterslev J
    BMC Med Res Methodol; 2014 Mar; 14():34. PubMed ID: 24588900
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Group sequential methods for cluster randomization trials with binary outcomes.
    Zou GY; Donner A; Klar N
    Clin Trials; 2005; 2(6):479-87. PubMed ID: 16422308
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Stopping rules for phase II studies.
    Stallard N; Whitehead J; Todd S; Whitehead A
    Br J Clin Pharmacol; 2001 Jun; 51(6):523-9. PubMed ID: 11422011
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A unified method for monitoring and analysing controlled trials.
    Grossman J; Parmar MK; Spiegelhalter DJ; Freedman LS
    Stat Med; 1994 Sep; 13(18):1815-26. PubMed ID: 7997715
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stopping clinical trials because of treatment ineffectiveness: a comparison of a futility design with a method of stochastic curtailment.
    Whitehead J; Matsushita T
    Stat Med; 2003 Mar; 22(5):677-87. PubMed ID: 12587099
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bayesian predictive probabilities: a good way to monitor clinical trials.
    Ferreira D; Ludes PO; Diemunsch P; Noll E; Torp KD; Meyer N
    Br J Anaesth; 2021 Feb; 126(2):550-555. PubMed ID: 33129491
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bayesian evaluation of group sequential clinical trial designs.
    Emerson SS; Kittelson JM; Gillen DL
    Stat Med; 2007 Mar; 26(7):1431-49. PubMed ID: 17066402
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Sample size adjustment designs with time-to-event outcomes: A caution.
    Freidlin B; Korn EL
    Clin Trials; 2017 Dec; 14(6):597-604. PubMed ID: 28795844
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Adaptive Bayesian randomized trials: realizing their potential.
    Pullenayegum EM
    J Bone Joint Surg Am; 2012 Jul; 94 Suppl 1():29-33. PubMed ID: 22810444
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Quantifying over-estimation in early stopped clinical trials and the "freezing effect" on subsequent research.
    Wang H; Rosner GL; Goodman SN
    Clin Trials; 2016 Dec; 13(6):621-631. PubMed ID: 27271682
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Data monitoring committees, interim analysis and early termination in paediatric trials.
    Fernandes RM; van der Lee JH; Offringa M
    Acta Paediatr; 2011 Oct; 100(10):1386-92. PubMed ID: 21434998
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Design of clinical trials with failure-time endpoints and interim analyses: An update after fifteen years.
    He P; Lai TL; Su Z
    Contemp Clin Trials; 2015 Nov; 45(Pt A):103-12. PubMed ID: 26031459
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Annals of Emergency Medicine Journal Club. Outcome measures, interim analyses, and Bayesian approaches to randomized trials: answers to the September 2009 Journal Club questions.
    Brown AM; Schriger DL; Barrett TW
    Ann Emerg Med; 2010 Feb; 55(2):216-224.e1. PubMed ID: 20116032
    [No Abstract]   [Full Text] [Related]  

  • 34. Comparing methods for calculating confidence intervals for vaccine efficacy.
    Ewell M
    Stat Med; 1996 Nov 15-30; 15(21-22):2379-92. PubMed ID: 8931208
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Termination of a randomized controlled trial of two vasectomy techniques.
    Chen-Mok M; Bangdiwala SI; Dominik R; Hays M; Irsula B; Sokal DC
    Control Clin Trials; 2003 Feb; 24(1):78-84. PubMed ID: 12559645
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A practical comparison of group-sequential and adaptive designs.
    Kelly PJ; Sooriyarachchi MR; Stallard N; Todd S
    J Biopharm Stat; 2005; 15(4):719-38. PubMed ID: 16022175
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sufficient trial size to inform clinical practice.
    Manski CF; Tetenov A
    Proc Natl Acad Sci U S A; 2016 Sep; 113(38):10518-23. PubMed ID: 27601679
    [TBL] [Abstract][Full Text] [Related]  

  • 38. A sequential procedure for comparing two experimental treatments with a control.
    Vincent E; Todd S; Whitehead J
    J Biopharm Stat; 2002 May; 12(2):249-65. PubMed ID: 12413243
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Data Monitoring Committees and early stopping guidelines: the Southwest Oncology Group experience.
    Crowley J; Green S; Liu PY; Wolf M
    Stat Med; 1994 Jul 15-30; 13(13-14):1391-9. PubMed ID: 7973218
    [TBL] [Abstract][Full Text] [Related]  

  • 40. The distribution of loss in two-treatment biased-coin designs.
    Atkinson AC
    Biostatistics; 2003 Apr; 4(2):179-93. PubMed ID: 12925515
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.